Three Antidepressants Show Superior Sustained Response in Major Depression
A large comparative study of antidepressant medication has identified the drugs’ ability to achieve and sustain improvements in patients with major depressive disorder (MDD). The analysis showed that escitalopram , duloxetine , and agomelatine were associated with higher rates of sustained treatment response than those observed with fluoxetine . Escitalopram and duloxetine were also associated with lower rates of treatment discontinuation. “These results may have implications for future guidelines and for the choice of a first antidepressant,” first author Paul C.F. van Haaren, MD, MSc, of Radboud University Medical Center, Nijmegen, Netherlands, told Medscape Medical News . “Many patients continue treatment after initial response to prevent relapse, so the first choice should reflect not only whether a drug gets people well but also whether it keeps them well in the long run,” van Haaren said. Of the three medications with the most favorable long-term efficacy, the selective serotonin reuptake inhibitor (SSRI) escitalopram “seems the most practical choice, as it is already widely used and SSRIs are the recommended first-line option in most treatment guidelines,” he said. The study was published online on November 10 in The Lancet Psychiatry . Differences in Sustained Response MDD is associated with a high risk for relapse and chronicity, underscoring the need for treatments that both achieve and maintain improvement. However, comparative evidence on the long-term efficacy of individual antidepressants remains limited. To address this gap, the researchers conducted a systematic review and network meta-analysis to compare the efficacy and acceptability of antidepressants in achieving and maintaining treatment response in adults with MDD. The investigators identified 115 randomized controlled trials involving 30,428 adults with MDD, of which 87 trials contributed data to the quantitative analyses. The mean age of the participants was 45 years, and 66% were women. They focused on sustained response, defined as improvement during acute treatment without subsequent relapse through the end of follow-up. Acceptability was assessed by discontinuation for any reason. The primary analysis included 35 head-to-head trials involving 9888 participants and 14 antidepressants. The median follow-up duration was 24-26 weeks, depending on trial design. Compared with fluoxetine (reference), the odds of sustained response were significantly higher with escitalopram (odds ratio [OR], 1.62), duloxetine (OR, 1.57), and agomelatine (OR, 1.40). Escitalopram and duloxetine were also associated with significantly lower all-cause discontinuation rates than fluoxetine, with ORs of 0.60 and 0.64, respectively. Bupropion and reboxetine showed lower sustained response rates than four other antidepressants each in pairwise comparisons, although neither differed significantly from fluoxetine. In a separate analysis of 39 relapse-prevention trials involving 10,428 participants who had already responded to antidepressant treatment, continuing medication was more effective than switching to placebo. The sustained response rate was 61.5% among those who continued antidepressant treatment compared with 44.7% among those switched to placebo (OR, 1.87). This new study builds on a 2018 analysis , which compared 21 antidepressants in 522 trials involving more than 116,000 adults with MDD and focused on acute treatment. As previously reported by Medscape Medical News , that analysis showed that all 21 antidepressants were more effective than placebo during acute treatment, typically assessed over 8 weeks. However, efficacy and acceptability differed among individual drugs. Escitalopram and agomelatine performed relatively well in both analyses, whereas duloxetine showed more favorable long-term acceptability. Bupropion appeared less effective at sustaining response than at achieving an initial response, although the evidence was limited. Implications for Clinical Practice “Choosing an antidepressant is definitely not one-size-fits-all,” said van Haaren. Decisions should be made jointly with patients, considering adverse effects, comorbidities, and individual preferences, he noted. Although agomelatine was among the more favorable medications in the current analysis, it is not approved in the US. In countries where it is available, treatment requires liver function monitoring because of the risk for hepatotoxicity, van Haaren noted. More than half (54%) of the studies included in the primary analysis were deemed to have a high risk for bias, and evidence was sparse for several antidepressants. Follow-up in the primary head-to-head trials was also relatively short, and comparative efficacy and acceptability beyond 12 months remain uncertain. Although the investigators found no evidence that effects diminish over time, van Haaren said, “we do not know for certain how these drugs compare beyond 12 months.” Beyond Trial and Error Despite these uncertainties, comparative efficacy data can help inform shared decision-making, said Manish Jha, MD, associate professor of psychiatry at UT Southwestern Medical Center in Dallas, who was not involved in the study. Such data should be considered along with adverse effects, discontinuation symptoms, previous treatment response, and comorbidities, he added. Jha cautioned against drawing firm conclusions about bupropion because relatively few patients received the drug in the included studies. More broadly, he noted that initial antidepressant prescribing often involves a “trial and error approach,” underscoring the urgent need for better markers to guide individualized treatment selection. Also commenting, Olu Ajilore, MD, PhD, member of the American Psychiatric Association Council on Research, said the study findings generally align with clinical practice and existing treatment guidelines. “Because of issues of tolerability and reduced drug-drug interactions, escitalopram is often used as first-line antidepressant treatment,” said Ajilore, of the University of Illinois Center for Depression and Resilience in Chicago. He added that the favorable long-term results for agomelatine are “interesting,” given it is not approved in the US. “These results may rekindle its development in the US,” he said. Sameer Jauhar, MD, clinical associate professor at Imperial College London, London, England, urged caution in translating the findings into clinical recommendations. Although the research provides useful information to inform treatment decisions, Jauhar said in a release from the Science Media Centre he “would not interpret these findings as a reason for someone who is responding well to their current antidepressant to change treatment.” The study received no specific funding. Author disclosures are available with the original study publication. Jha reported having no relevant disclosures. Ajilore disclosed being a cofounder of KeyWise AI, consulting for Otsuka, and serving on advisory boards for Blueprint Health and Embodied Labs. Jauhar disclosed having financial relationships with Recordati, LB Pharmaceuticals, Boehringer Ingelheim, Accord Pharmaceuticals, Wellcome Trust, Lundbeck, Janssen, and Sunovion, among others. He also reported serving as a reviewer of the study.